Author:
Grivas Petros,Kopyltsov Evgeny,Su Po-Jung,Parnis Francis X.,Park Se Hoon,Yamamoto Yoshiaki,Fong Peter C.,Tournigand Christophe,Climent Duran Miguel A.,Bamias Aristotelis,Caserta Claudia,Chang Jane,Cislo Paul,di Pietro Alessandra,Wang Jing,Powles Thomas
Reference39 articles.
1. National Cancer Institute. SEER cancer stat facts: bladder cancer. Bethesda, MD. https://seer.cancer.gov/statfacts/html/urinb.html.
2. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial;Dogliotti;Eur Urol,2007
3. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005
4. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986;De Santis;J Clin Oncol,2012
5. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2021
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献